tetano
Editor, Senior Moderator
Expert Rev Vaccines. 2019 Jun 3:1-8. doi: 10.1080/14760584.2019.1622418. [Epub ahead of print]
[h=1]Adjuvanted versus nonadjuvanted influenza vaccines and risk of hospitalizations for pneumonia and cerebro/cardiovascular events in the elderly.[/h] Lapi F[SUP]1[/SUP], Marconi E[SUP]1[/SUP], Simonetti M[SUP]1[/SUP], Baldo V[SUP]2[/SUP], Rossi A[SUP]3[/SUP], Sessa A[SUP]3[/SUP], Cricelli C[SUP]3[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Background: The higher effectiveness of MF59?-adjuvanted trivalent influenza vaccine (MF59-TIV) vs. nonadjuvanted TIV in preventing influenza-related hospitalizations was found considering few influenza seasons, local and heterogeneous settings. This study evaluated the relative vaccine effectiveness (rVE) of MF59-TIV vs. nonadjuvanted TIV on the risk of hospitalization for pneumonia and cerebro/cardiovascular events across 15 consecutive influenza seasons. Research design and methods: Using Health Search Database, a case-control study was nested in a cohort of elderly vaccinated with MF59-TIV or TIV. Conditional logistic regression was used to estimate the odds ratio with 95% confidence intervals (CI) of hospitalizations potentially related to influenza in patients vaccinated with MF59-TIV or TIV. Results: Of 43,000 patients vaccinated with MF59-TIV (66.2%) and TIV (33.8%) for the first time, 103 cases of hospitalization for pneumonia or cerebro/cardiovascular events (0.11 per 1,000 person-weeks) during 15 influenza seasons were identified. The MF59-TIV was associated with a reduced risk of hospitalizations for pneumonia and cerebro/cardiovascular events vs. TIV [rVE: 39% (95% CI: 4-61%)]. Conclusions: In a 15-season cohort of elderly, MF59-TIV seems to reduce the risk of hospitalizations for pneumonia and cerebro/cardiovascular events when compared with nonadjuvanted TIV. Our findings support the recommendation for MF59-TIV in the elderly population.
[h=4]KEYWORDS:[/h] Influenza vaccines; hospitalization; myocardial infarction; pneumonia; primary care; stroke
PMID: 31155968 DOI: 10.1080/14760584.2019.1622418
[h=1]Adjuvanted versus nonadjuvanted influenza vaccines and risk of hospitalizations for pneumonia and cerebro/cardiovascular events in the elderly.[/h] Lapi F[SUP]1[/SUP], Marconi E[SUP]1[/SUP], Simonetti M[SUP]1[/SUP], Baldo V[SUP]2[/SUP], Rossi A[SUP]3[/SUP], Sessa A[SUP]3[/SUP], Cricelli C[SUP]3[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Background: The higher effectiveness of MF59?-adjuvanted trivalent influenza vaccine (MF59-TIV) vs. nonadjuvanted TIV in preventing influenza-related hospitalizations was found considering few influenza seasons, local and heterogeneous settings. This study evaluated the relative vaccine effectiveness (rVE) of MF59-TIV vs. nonadjuvanted TIV on the risk of hospitalization for pneumonia and cerebro/cardiovascular events across 15 consecutive influenza seasons. Research design and methods: Using Health Search Database, a case-control study was nested in a cohort of elderly vaccinated with MF59-TIV or TIV. Conditional logistic regression was used to estimate the odds ratio with 95% confidence intervals (CI) of hospitalizations potentially related to influenza in patients vaccinated with MF59-TIV or TIV. Results: Of 43,000 patients vaccinated with MF59-TIV (66.2%) and TIV (33.8%) for the first time, 103 cases of hospitalization for pneumonia or cerebro/cardiovascular events (0.11 per 1,000 person-weeks) during 15 influenza seasons were identified. The MF59-TIV was associated with a reduced risk of hospitalizations for pneumonia and cerebro/cardiovascular events vs. TIV [rVE: 39% (95% CI: 4-61%)]. Conclusions: In a 15-season cohort of elderly, MF59-TIV seems to reduce the risk of hospitalizations for pneumonia and cerebro/cardiovascular events when compared with nonadjuvanted TIV. Our findings support the recommendation for MF59-TIV in the elderly population.
[h=4]KEYWORDS:[/h] Influenza vaccines; hospitalization; myocardial infarction; pneumonia; primary care; stroke
PMID: 31155968 DOI: 10.1080/14760584.2019.1622418